Tumor-Agnostic: AMXT 1501 & the Future of Cancer Care

We are joined by two leaders from Aminex Therapeutics, Mark Burns, President & CSO, and Jeff Judson, VP of Strategic Planning & Investor Relations, to discuss the groundbreaking development of Aminex 1501, a novel cancer therapy that is transforming oncology. This conversation dives into the science behind this innovative therapy, its distinctive funding journey, the promising clinical trial results, and the collaboration with CTI. Listen now to explore the significance of FDA orphan drug designation and what it means for advancing innovative treatments for rare cancers. 00:10 Aminex 1501 is introduced, along with its mission to fight cancer by removing essential growth factors from tumors, stimulating the immune system 00:43 The drug’s effectiveness across a wide range of solid tumors, showcasing its tumor-agnostic approach 01:11 Mark shares the origin of Aminex, highlighting its unique funding by angel investors outside biotech and the absence of venture capital 02:01 Why they chose CTI as a partner: technical competence, responsiveness, and Midwest values 03:18 How the therapy removes polyamines from tumors, leading to profound immune responses in animal models 04:11 The team discusses receiving FDA orphan drug designation for neuroblastoma and ongoing pediatric trials at Penn State University 05:15 Insights into the treatment of six rare childhood cancers, with a focus on improving quality of life and minimizing side effects 05:56 Breast cancer and melanoma identified as promising indications for future focus, with neuroblastoma and others also in scope 06:23 Recap of clinical trial progress and milestones  07:19 Recognition of patients as heroes in advancing cancer therapeutics 08:03 How the therapy trains the immune system to recognize and attack cancer 08:57 The inspiration behind targeting polyamines and the development of DFMO and Aminex 1501 10:00 Anecdotes about early animal studies, dramatic tumor shrinkage, and the motivation to continue research 12:13 The team’s passion for improving patient outcomes and the importance of collaboration 13:00 Information for patients interested in joining trials, with details on upcoming clinics and how to find more information on clinicaltrials.gov